Page 344 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 344
Clinical Trials in Progress (Cont.)
P1318 PHASE I DOSE ESCALATION STUDY OF THE SAFETY,
IMMUNOREGULATORY ACTIVITY, PHARMACOKINETICS,
AND PRELIMINARY ANTITUMOR ACTIVITY OF
NIVOLUMAB IN ADVANCED HEPATOCELLULAR
CARCINOMA IN PATIENTS WITH OR WITHOUT CHRONIC
VIRAL HEPATITIS
Bruno Sangro*, Anthony B. El-Khoueiry, Todd S. Crocenzi,
Theodore H. Welling III, William Feely, Jeffrey A. Anderson,
Christine dela Cruz, Ignacio Melero, Spain
P1319 ALFAPUMP® SYSTEM VERSUS LARGE VOLUME
PARACENTESIS IN THE TREATMENT OF REFRACTORY
ASCITES. A MULTICENTER RANDOMISED CONTROLLED
STUDY
Danielle Adebayo*, Christophe Bureau, Dominique Valla, Markus Peck-
Radosavljevic, Anne McCune, Victor Vargas, Paolo Angeli,
Steven Whittaker, Rajiv Jalan, The United Kingdom
P1320 EARLY EVEROLIMUS-BASED TACROLIMUS REDUCTION IN
DE NOVO LIVER TRANSPLANT RECIPIENTS: DESIGN AND
ePOSTERS BASELINE DATA FROM HEPHAISTOS STUDY
Bjorn Nashan*, Peter Schemmer, Felix Braun, Markus Dworak,
Peter Wimmer, Hans Schlitt, Germany
P1321 A PHASE 3B, DOUBLE BLIND, PLACEBO CONTROLLED
STUDY EVALUATING THE EFFECT OF OBETICHOLIC ACID
ON CLINICAL OUTCOMES IN SUBJECTS WITH PRIMARY
BILIARY CIRRHOSIS AT ELEVATED RISK OF PROGRESSION
TO LIVER TRANSPLANT OR DEATH
Keith Lindor*, Bettina Hansen, Richard Pencek, Roya Hooshmand-
Rad, Tonya Marmon, Leigh MacConell, David Shapiro, David Jones,
The United States
P1322 CONTRAST (SONZOID)-ENHANCED US AS A SCREENING
TOOL FOR HEPATOCELLULAR CARCINOMA IN
CIRRHOSIS: AN EXPLORATORY CLINICAL TRIAL (SCAN
TRIAL)
Mi-Suk Park*, Jihoon Park, Sojung Lee, Wookyung Chung, Jaeyoung Lee,
South Korea
344 The International Liver Congress™ 2015 • ILC Programme
P1318 PHASE I DOSE ESCALATION STUDY OF THE SAFETY,
IMMUNOREGULATORY ACTIVITY, PHARMACOKINETICS,
AND PRELIMINARY ANTITUMOR ACTIVITY OF
NIVOLUMAB IN ADVANCED HEPATOCELLULAR
CARCINOMA IN PATIENTS WITH OR WITHOUT CHRONIC
VIRAL HEPATITIS
Bruno Sangro*, Anthony B. El-Khoueiry, Todd S. Crocenzi,
Theodore H. Welling III, William Feely, Jeffrey A. Anderson,
Christine dela Cruz, Ignacio Melero, Spain
P1319 ALFAPUMP® SYSTEM VERSUS LARGE VOLUME
PARACENTESIS IN THE TREATMENT OF REFRACTORY
ASCITES. A MULTICENTER RANDOMISED CONTROLLED
STUDY
Danielle Adebayo*, Christophe Bureau, Dominique Valla, Markus Peck-
Radosavljevic, Anne McCune, Victor Vargas, Paolo Angeli,
Steven Whittaker, Rajiv Jalan, The United Kingdom
P1320 EARLY EVEROLIMUS-BASED TACROLIMUS REDUCTION IN
DE NOVO LIVER TRANSPLANT RECIPIENTS: DESIGN AND
ePOSTERS BASELINE DATA FROM HEPHAISTOS STUDY
Bjorn Nashan*, Peter Schemmer, Felix Braun, Markus Dworak,
Peter Wimmer, Hans Schlitt, Germany
P1321 A PHASE 3B, DOUBLE BLIND, PLACEBO CONTROLLED
STUDY EVALUATING THE EFFECT OF OBETICHOLIC ACID
ON CLINICAL OUTCOMES IN SUBJECTS WITH PRIMARY
BILIARY CIRRHOSIS AT ELEVATED RISK OF PROGRESSION
TO LIVER TRANSPLANT OR DEATH
Keith Lindor*, Bettina Hansen, Richard Pencek, Roya Hooshmand-
Rad, Tonya Marmon, Leigh MacConell, David Shapiro, David Jones,
The United States
P1322 CONTRAST (SONZOID)-ENHANCED US AS A SCREENING
TOOL FOR HEPATOCELLULAR CARCINOMA IN
CIRRHOSIS: AN EXPLORATORY CLINICAL TRIAL (SCAN
TRIAL)
Mi-Suk Park*, Jihoon Park, Sojung Lee, Wookyung Chung, Jaeyoung Lee,
South Korea
344 The International Liver Congress™ 2015 • ILC Programme
